

EQA round: BM1/25 - Bone Markers

Deadline: 11.4.2025

Setup: groups - R (manufacturer of kit); Slovakia; minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVPG = consensus of the participants' groups	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL			
(435) 25-hydroxyvitamin D	[nmol/L]				26							25	21	84
Sample A		123	22	18	26							25	23	92
(1) Abbott		108	0,89	0,82	6	0	CVPG	110	1,9	25%	82,5	138	6	
(60) Roche		118	12	10	14	0	CVPG	115	2,5	25%	86,2	144	14	
Other					6	0							5	
							4x 12, 1x 179, 1x 998							
Sample B		65,2	17	27	26							25	21	84
(1) Abbott		52,3	2	3,8	6	0	CVPG	51	1,1	25%	38,2	63,8	6	
(60) Roche		63,5	11	18	14	0	CVPG	61,2	1,9	25%	45,9	76,5	14	
Other					6	0							5	
							4x 12, 1x 179, 1x 998							
(434) Osteocalcin	[µg/L]				18							16	15	94
Sample A		86,5	6,5	7,6	18							16	15	94
(60) Roche		86,6	5,4	6,2	16	0	CVPG	86,9	1,6	13%	75,6	98,2	16	
Other					2	0							0	
							1x 73, 1x 164							
Sample B		19,6	1,1	5,5	18							16	15	94
(60) Roche		19,8	0,93	4,7	16	0	CVPG	19,8	0,24	13%	17,2	22,4	16	
Other					2	0							0	
							1x 73, 1x 164							
(433) P1NP	[µg/L]				13							13	13	100
Sample A		182	18	9,8	13							13	13	100
(60) Roche		179	16	8,8	12	0	CVPG	180	3,5	20%	144	216	12	
Other					1	0							1	
							1x 73							
Sample B		27,9	2,9	10	13							13	13	100
(60) Roche		27,5	2,5	9,1	12	0	CVPG	26,7	0,54	20%	21,3	32,1	12	
Other					1	0							1	
							1x 73							
(436) Parathyrin biointact (PTH 1-84)	[pmol/L]				2							2	1	50
Sample A		13	1,3	9,7	2							2	1	50
Other					2	0							2	
							1x 60, 1x 164							
Sample B		4,17	0,47	11	2							2	2	100
Other					2	0							2	
							1x 60, 1x 164							
(431) Parathyrin intact (PTH)	[pmol/L]				24							22	20	91
Sample A		20	6,6	33	24							22	20	91
(60) Roche		19,6	2,2	11	11	0	CVPG	20	0,39	23%	15,4	24,6	11	
Other					13	2							11	
							4x 1, 4x 12, 1x 29, 1x 58, 3x 179							
Sample B		6,45	2,4	38	24							22	20	91
(60) Roche		5,73	0,7	12	11	0	CVPG	5,76	0,17	23%	4,43	7,09	11	
Other					13	1							11	
							4x 1, 4x 12, 1x 29, 1x 58, 3x 179							
(432) Collagen telopeptide CTx-β	[ng/L]				19							19	17	89
Sample A		649	89	14	19							19	18	95
(60) Roche		656	84	13	18	0	CVPG	691	23	17%	573	809	18	
Other					1	0							1	
							1x 73							
Sample B		300	37	12	19							19	18	95
(60) Roche		304	34	11	18	0	CVPG	319	6,9	17%	264	374	18	
Other					1	0							1	
							1x 73							